See more : Sunsweet Public Company Limited (SUN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Austar Lifesciences Limited (6118.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Austar Lifesciences Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- ACE Convergence Acquisition Corp. (ACEVU) Income Statement Analysis – Financial Results
- Novo Resources Corp. (NVOOF) Income Statement Analysis – Financial Results
- Icelandic Salmon AS (ISLAX.OL) Income Statement Analysis – Financial Results
- LERTHAI FINANCE LIMITED (LERTHAI.BO) Income Statement Analysis – Financial Results
- Compass Group PLC (CMPGF) Income Statement Analysis – Financial Results
Austar Lifesciences Limited (6118.HK)
About Austar Lifesciences Limited
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.76B | 2.23B | 2.02B | 1.30B | 1.05B | 816.59M | 546.93M | 672.55M | 627.54M | 679.75M | 705.15M |
Cost of Revenue | 1.43B | 1.77B | 1.54B | 972.45M | 764.78M | 612.19M | 425.40M | 512.84M | 473.30M | 451.14M | 490.19M |
Gross Profit | 336.05M | 462.67M | 479.01M | 323.53M | 284.24M | 204.39M | 121.53M | 159.71M | 154.25M | 228.61M | 214.97M |
Gross Profit Ratio | 19.05% | 20.76% | 23.77% | 24.96% | 27.10% | 25.03% | 22.22% | 23.75% | 24.58% | 33.63% | 30.49% |
Research & Development | 55.33M | 70.16M | 65.60M | 48.27M | 42.58M | 30.31M | 26.06M | 32.04M | 26.91M | 23.59M | 23.90M |
General & Administrative | 133.67M | 134.61M | 128.09M | 98.70M | 108.73M | 77.45M | 70.80M | 67.95M | 56.21M | 57.28M | 47.85M |
Selling & Marketing | 167.32M | 178.66M | 170.29M | 148.69M | 137.08M | 105.64M | 100.47M | 82.69M | 71.00M | 65.13M | 72.10M |
SG&A | 300.99M | 310.12M | 304.08M | 259.32M | 250.95M | 183.09M | 171.42M | 150.79M | 127.22M | 122.41M | 119.95M |
Other Expenses | 9.72M | -2.80M | 2.28M | 3.03M | 420.00K | 256.00K | 414.00K | 414.00K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 366.04M | 368.21M | 156.85M | 282.36M | 274.39M | 204.52M | 183.06M | 180.21M | 148.07M | 140.21M | 138.66M |
Cost & Expenses | 1.79B | 2.13B | 1.69B | 1.25B | 1.04B | 816.72M | 608.46M | 693.05M | 621.37M | 591.35M | 628.85M |
Interest Income | 3.11M | 7.97M | 2.93M | 322.00K | 2.35M | 3.63M | 3.11M | 3.00M | 1.41M | 573.00K | 351.00K |
Interest Expense | 13.96M | 10.25M | 4.40M | 2.79M | 3.35M | 1.45M | 1.22M | 1.05M | 2.02M | 1.88M | 1.35M |
Depreciation & Amortization | 45.60M | 37.01M | 31.58M | 31.90M | 26.30M | 9.60M | 8.86M | 11.62M | 9.95M | 7.32M | 5.72M |
EBITDA | 25.15M | 166.14M | 130.62M | 39.83M | 14.40M | 1.56M | -60.21M | -9.66M | 14.48M | 91.97M | 77.60M |
EBITDA Ratio | 1.43% | 4.76% | 6.48% | 3.07% | 1.37% | 0.19% | -11.01% | -1.44% | 2.31% | 13.53% | 11.01% |
Operating Income | -29.99M | 90.39M | 116.97M | 26.38M | 2.65M | -6.02M | -68.12M | -20.53M | 4.53M | 84.65M | 71.89M |
Operating Income Ratio | -1.70% | 4.06% | 5.80% | 2.04% | 0.25% | -0.74% | -12.45% | -3.05% | 0.72% | 12.45% | 10.19% |
Total Other Income/Expenses | -4.42M | -29.89M | 202.26M | 15.11M | 9.56M | 15.08M | 9.09M | 5.60M | 3.06M | 3.17M | 4.77M |
Income Before Tax | -34.41M | 86.49M | 319.23M | 41.49M | 12.21M | 3.50M | -58.42M | -17.50M | 7.59M | 87.83M | 76.65M |
Income Before Tax Ratio | -1.95% | 3.88% | 15.84% | 3.20% | 1.16% | 0.43% | -10.68% | -2.60% | 1.21% | 12.92% | 10.87% |
Income Tax Expense | 379.00K | 18.74M | 46.60M | 9.88M | 4.74M | 3.38M | 4.22M | 1.17M | 1.21M | 22.63M | 23.08M |
Net Income | -113.47M | 87.46M | 277.30M | 33.10M | 8.09M | 107.00K | -54.09M | -18.67M | 6.38M | 65.19M | 53.57M |
Net Income Ratio | -6.43% | 3.92% | 13.76% | 2.55% | 0.77% | 0.01% | -9.89% | -2.78% | 1.02% | 9.59% | 7.60% |
EPS | -0.02 | 0.17 | 0.54 | 0.06 | 0.02 | 0.00 | -0.11 | -0.04 | 0.01 | 0.17 | 0.14 |
EPS Diluted | -0.06 | 0.17 | 0.54 | 0.06 | 0.02 | 0.00 | -0.11 | -0.04 | 0.01 | 0.17 | 0.14 |
Weighted Avg Shares Out | 1.78B | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M | 491.68M | 512.58M | 512.58M | 394.42M | 375.00M |
Weighted Avg Shares Out (Dil) | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M | 394.42M | 375.00M |
Source: https://incomestatements.info
Category: Stock Reports